(Q39637210)

English

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy

scientific article published on July 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy (English)

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

phase II clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Michael C. Heinrich

4

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

10

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

author name string

E Ben-Ami

1

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

C M Barysauskas

2

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

M von Mehren

3

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

C L Corless

5

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

J E Butrynski

6

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

J A Morgan

7

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

A J Wagner

8

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

E Choy

9

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

A D Van den Abbeele

11

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

S M Solomon

12

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

J A Fletcher

13

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

G D Demetri

14

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

S George

15

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

publication date

1 July 2016

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

Annals of Oncology

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

27

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

9

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

1794-1799

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW228

21 January 2018

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW228

21 January 2018

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW228

21 January 2018

Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW228

21 January 2018

Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW228

21 January 2018

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW228

21 January 2018

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW228

21 January 2018

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW228

21 January 2018

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW228

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW228

21 January 2018

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW228

21 January 2018

CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW228

21 January 2018

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW228

21 January 2018

Succinate dehydrogenase-deficient gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW228

21 January 2018

Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW228

21 January 2018

Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW228

21 January 2018

Identifiers

10.1093/ANNONC/MDW228

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

1 reference

Europe PubMed Central

2 July 2019

http://europepmc.org/abstract/PMC/6279099

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39637210&oldid=1848728302"